Literature DB >> 17624990

LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking.

A K Lindström1, K Ekman, U Stendahl, T Tot, R Henriksson, H Hedman, D Hellberg.   

Abstract

The aim is to evaluate LRIG1 as a prognosis predictor and correlations to cofactors in squamous cell cervical cancer. LRIG1 expression was studied in 128 cervical carcinomas and was compared with expression of nine other tumor markers. Smoking history was registered and pretreatment serum estradiol and progesterone levels were evaluated in 79 women. At clinical stage IB, 58% of the tumors showed LRIG1 expression, but there was a decline by increasing stage (33% in stage IV). Ninety percent of women with stage IB cancer and LRIG1 positivity survived, as compared to 64% without expression (P = 0.02). LRIG1 expression did not predict prognosis in advanced stages, but in stage IIA there was a marked relative difference, with 75% survival in tumors expressing LRIG1, as compared to 43% in those without. No correlation was found between LRIG1 and the other nine tumor markers studied. A high serum progesterone and smoking correlated to absent LRIG1 expression. We conclude that LRIG1 appears to be a significant prognosis predictor in early-stage cervical cancer, independent of the other tumor markers that were studied. Diminished expression in advanced stages and the inverse correlation to serum progesterone and smoking indicates that LRIG1 is a tumor suppressor in cervix.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17624990     DOI: 10.1111/j.1525-1438.2007.01021.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  34 in total

1.  Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer.

Authors:  Malin Lando; Christina S Fjeldbo; Saskia M Wilting; Barbara C Snoek; Eva-Katrine Aarnes; Malin F Forsberg; Gunnar B Kristensen; Renske Dm Steenbergen; Heidi Lyng
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

2.  Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer.

Authors:  Sheryl R Krig; Seth Frietze; Catalina Simion; Jamie K Miller; Will H D Fry; Hanine Rafidi; Lakmal Kotelawala; Lihong Qi; Obi L Griffith; Joe W Gray; Kermit L Carraway; Colleen Sweeney
Journal:  Mol Cancer Res       Date:  2011-08-05       Impact factor: 5.852

3.  Loss of Lrig1 leads to expansion of Brunner glands followed by duodenal adenomas with gastric metaplasia.

Authors:  Yang Wang; Chanjuan Shi; Yuanyuan Lu; Emily J Poulin; Jeffery L Franklin; Robert J Coffey
Journal:  Am J Pathol       Date:  2015-04       Impact factor: 4.307

4.  Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression.

Authors:  Soma Ghasimi; Hannu Haapasalo; Mine Eray; Katariina Korhonen; Thomas Brännström; Håkan Hedman; Ulrika Andersson
Journal:  J Neurooncol       Date:  2012-04-08       Impact factor: 4.130

5.  Vertebrate Lrig3-ErbB interactions occur in vitro but are unlikely to play a role in Lrig3-dependent inner ear morphogenesis.

Authors:  Victoria E Abraira; Takunori Satoh; Donna M Fekete; Lisa V Goodrich
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

6.  LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII.

Authors:  M A Stutz; D L Shattuck; M B Laederich; K L Carraway; C Sweeney
Journal:  Oncogene       Date:  2008-06-09       Impact factor: 9.867

7.  Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.

Authors:  Jamie K Miller; David L Shattuck; Ellen Q Ingalla; Lily Yen; Alexander D Borowsky; Lawrence J T Young; Robert D Cardiff; Kermit L Carraway; Colleen Sweeney
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

8.  Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).

Authors:  Hanine Rafidi; Francisco Mercado; Michael Astudillo; William H D Fry; Matthew Saldana; Kermit L Carraway; Colleen Sweeney
Journal:  J Biol Chem       Date:  2013-05-30       Impact factor: 5.157

9.  Intracellular LINGO-1 negatively regulates Trk neurotrophin receptor signaling.

Authors:  James S Meabon; Rian de Laat; Katsuaki Ieguchi; Dmitry Serbzhinsky; Mark P Hudson; B Russel Huber; Jesse C Wiley; Mark Bothwell
Journal:  Mol Cell Neurosci       Date:  2015-11-03       Impact factor: 4.314

10.  A genome assembly-integrated dog 1 Mb BAC microarray: a cytogenetic resource for canine cancer studies and comparative genomic analysis.

Authors:  R Thomas; S E Duke; E K Karlsson; A Evans; P Ellis; K Lindblad-Toh; C F Langford; M Breen
Journal:  Cytogenet Genome Res       Date:  2008-12-18       Impact factor: 1.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.